Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

MT Newswires Live08-10

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation keep the outlook balanced, Morgan Stanley said in a note emailed Monday.

STIX should help bring more patients to Daybue rather than mainly shift users away from the oral version, supporting further growth in the Rett syndrome business, Morgan Stanley said, adding that the firm expects Nuplazid to remain a steady growth driver and stay on track toward about $1 billion in sales.

The upcoming phase 2 RADIANT results for Remlifanserin will be a major factor for the stock, with efficacy, safety, responder, cognitive and motor data helping investors judge the drug's potential, according to the note.

The investment firm said it expects Acadia's financial position to improve as sales rise, estimating operating margin will increase to 15% in 2028 from 9% in 2026, while free cash flow could grow to $280 million from $131 million and Acadia's net-cash position should give the company room to fund growth and manage its drug pipeline.

Morgan Stanley kept its equal-weight rating and $27 price target, saying stronger business performance is balanced by the stock trading above its target and the risk around the upcoming RADIANT results.

Price: 29.53, Change: +0.32, Percent Change: +1.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658552930?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658552930","market":"sg","top_or_hot":-1,"title":"Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation keep the outlook balanced, Morgan Stanley said in a note emailed Monday.</p><p>STIX should help bring more patients to Daybue rather than mainly shift users away from the oral version, supporting further growth in the Rett syndrome business, Morgan Stanley said, adding that the firm expects Nuplazid to remain a steady growth driver and stay on track toward about $1 billion in sales.</p><p>The upcoming phase 2 RADIANT results for Remlifanserin will be a major factor for the stock, with efficacy, safety, responder, cognitive and motor data helping investors judge the drug's potential, according to the note.</p><p>The investment firm said it expects Acadia's financial position to improve as sales rise, estimating operating margin will increase to 15% in 2028 from 9% in 2026, while free cash flow could grow to $280 million from $131 million and Acadia's net-cash position should give the company room to fund growth and manage its drug pipeline.</p><p>Morgan Stanley kept its equal-weight rating and $27 price target, saying stronger business performance is balanced by the stock trading above its target and the risk around the upcoming RADIANT results.</p><p>Price: 29.53, Change: +0.32, Percent Change: +1.10</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-10 23:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation keep the outlook balanced, Morgan Stanley said in a note emailed Monday.</p><p>STIX should help bring more patients to Daybue rather than mainly shift users away from the oral version, supporting further growth in the Rett syndrome business, Morgan Stanley said, adding that the firm expects Nuplazid to remain a steady growth driver and stay on track toward about $1 billion in sales.</p><p>The upcoming phase 2 RADIANT results for Remlifanserin will be a major factor for the stock, with efficacy, safety, responder, cognitive and motor data helping investors judge the drug's potential, according to the note.</p><p>The investment firm said it expects Acadia's financial position to improve as sales rise, estimating operating margin will increase to 15% in 2028 from 9% in 2026, while free cash flow could grow to $280 million from $131 million and Acadia's net-cash position should give the company room to fund growth and manage its drug pipeline.</p><p>Morgan Stanley kept its equal-weight rating and $27 price target, saying stronger business performance is balanced by the stock trading above its target and the risk around the upcoming RADIANT results.</p><p>Price: 29.53, Change: +0.32, Percent Change: +1.10</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171402.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658552930","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658552930","pubTimestamp":1786376001,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","AKR":"阿卡迪亚房地产信托","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4231":"零售房地产信托","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","ACAD":"阿卡迪亚","BK4080":"零售业房地产投资信托","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC"},"translate_title":"阿卡迪亚制药公司将受益于 Daybue、Nuplazid 的增长；摩根士丹利表示，辐射数据增加了风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1.5,"ACAD":1},"content_text":"Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation keep the outlook balanced, Morgan Stanley said in a note emailed Monday.STIX should help bring more patients to Daybue rather than mainly shift users away from the oral version, supporting further growth in the Rett syndrome business, Morgan Stanley said, adding that the firm expects Nuplazid to remain a steady growth driver and stay on track toward about $1 billion in sales.The upcoming phase 2 RADIANT results for Remlifanserin will be a major factor for the stock, with efficacy, safety, responder, cognitive and motor data helping investors judge the drug's potential, according to the note.The investment firm said it expects Acadia's financial position to improve as sales rise, estimating operating margin will increase to 15% in 2028 from 9% in 2026, while free cash flow could grow to $280 million from $131 million and Acadia's net-cash position should give the company room to fund growth and manage its drug pipeline.Morgan Stanley kept its equal-weight rating and $27 price target, saying stronger business performance is balanced by the stock trading above its target and the risk around the upcoming RADIANT results.Price: 29.53, Change: +0.32, Percent Change: +1.10","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658552930","isCrawlerRequest":true}